Indications for islet or pancreatic transplantation: Statement of the TREPID working group on behalf of the Société francophone du diabète (SFD), Société francaise d’endocrinologie (SFE), Société francophone de transplantation (SFT) and Société française de néphrologie – dialyse – transplantation (SFNDT)
Year: 2018
Type: article
Abstract: While either pancreas or pancreatic islet transplantation can restore endogenous insulin secretion in patients with diabetes, no beta-cell replacement strategies are recommended in the literature. For this reason, the aim of this national expert panel statement is to provide information on the different kinds of beta-cell replacement, their benefit-risk ratios and indications for each type of transplantation, according to type of diabetes, its control and association with end-stage renal disease. Allotransplantation requires immunosuppression, a risk that should be weighed against the risks of poor glycaemic control, diabetic lability and severe hypoglycaemia, especially in cases of unawareness. Pancreas transplantation is associated with improvement in diabetic micro- and macro-angiopathy, but has the associated morbidity of major surgery. Islet transplantation is a minimally invasive radiological or mini-surgical procedure involving infusion of purified islets via the hepatic portal vein, but needs to be repeated two or three times to achieve insulin independence and long-term functionality. Simultaneous pancreas-kidney and pancreas after kidney transplantations should be proposed for kidney recipients with type 1 diabetes with no surgical, especially cardiovascular, contraindications. In cases of high surgical risk, islet after or simultaneously with kidney transplantation may be proposed. Pancreas, or more often islet, transplantation alone is appropriate for non-uraemic patients with labile diabetes. Various factors influencing the therapeutic strategy are also detailed in this report.
Source: Diabetes & Metabolism
Authors: A. Wojtusciszyn, J. Branchereau, L. Esposito, L. Badet, F. Buron, M. Chetboun, L. Kessler, E. Morelon, T. Berney, F. Pattou, P.-Y. Benhamou, M.-C. Vantyghem, Axel Andres, Mathieu Armanet, Gilles Blancho, Sophie Caillard, Bogdan Catargi, Pierre Cattan, Chailloux Lucy, Choukroun Gabriel, Oriana Ciacio, Emmanuel Cuellar, Gianluca Donatini, Jean-Pierre Duffas, Antoine Durrbach, Michelle Elias, Marie Frimat, Valérie Garrigue, Francois Gaudez, Hélène Hanaire, Nassim Kamar, Georges Karam, Sandrine Lablanche, Anne Lejay, Kristell Le Mapihan, Paolo Malvezzi, Vincent Melki, Karine Moreau, Fabrice Muscari, Sophie Ohlmann, Fabrizio Panaro, Marie-Noelle Peraldi, Gabriella Pittau, Gaetan Prévost, Sophie Reffet, Jean-Pierre Riveline, Antonio Sacunha, Jean-Emmanuel Serre, Rachel Tetaz, Olivier Thaunat, Xavier Tillou, Tiphaine Vidal-Trecan
Institutions: Centre National de la Recherche Scientifique, Inserm, Université de Montpellier, Centre Hospitalier Universitaire de Montpellier, Institute for Regenerative Medicine & Biotherapy, Hôpital Lapeyronie, Hôpital Saint Eloi, Institut de Génomique Fonctionnelle, Centre Hospitalier Universitaire de Nantes, Institut de Transplantation Urologie en Nephrologie, Center for Research in Transplantation and Translational Immunology, Université de Nantes, Nantes Université, Hospices Civils de Lyon, Hôpital Lyon Sud, Université de Lille, Centre Hospitalier Universitaire de Lille, Recherche translationnelle sur le diabète et les troubles métaboliques, Université Lille Nord de France, Regenerative NanoMedicine, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, University Hospital of Geneva, Centre Hospitalier Universitaire de Grenoble, Laboratory of Fundamental and Applied Bioenergetics, Université Grenoble Alpes, Hôpital Claude Huriez
Language: French
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: islet transplantation, pancreas transplantation, beta cell replacement therapy, type 1 diabetes, type 2 diabetes, end-stage renal disease, simultaneous pancreas-kidney transplantation, immunosuppression, hypoglycemia, diabetic nephropathy, diabetic vascular disease, insulin independence, transplant indications
Open Access status: hybrid
Estimated APC paid: $4,490
OpenAlex ID: W2890433485
